Acifix is an enteric-coated tablet containing rabeprazole sodium 20 mg, a proton pump inhibitor that reduces the amount of acid the stomach produces. Doctors prescribe it for acid-related stomach and food-pipe problems.
There are 48 brands of Rabeprazole Sodium listed in Bangladesh. 10 of them have a lower unit price than Acifix. The lowest listed price is Acifix 10 mg Sprinkle Capsule at ৳ 3.50 per unit.
What is Acifix 20 mg Tablet (Enteric Coated)?
Acifix 20 mg is an enteric-coated tablet made by Beximco Pharmaceuticals PLC. Its active ingredient is rabeprazole sodium, which belongs to a group of medicines called proton pump inhibitors. These work by blocking the small pumps in the stomach lining that release acid, so the stomach makes less acid. Doctors use it for conditions such as active duodenal ulcer, active benign gastric ulcer, and erosive or ulcerative gastro-oesophageal reflux disease, including long-term management of reflux. It is also used for symptomatic treatment of moderate to very severe reflux disease. The dose and course are decided by the doctor.
Uses of Acifix
Acifix is used to treat active duodenal ulcer and active benign gastric ulcer. It is also used for symptomatic erosive or ulcerative gastro-oesophageal reflux disease, for long-term management of reflux disease, and for symptomatic treatment of moderate to very severe reflux disease. It is a proton pump inhibitor, a medicine that lowers stomach acid. Your doctor will decide whether it suits your condition and how long you should take it.
How to use Acifix
Swallow the enteric-coated tablet as your doctor advises; the doctor decides the dose and how long the course lasts. Do not crush or chew the tablet unless your doctor or pharmacist tells you to, because the coating protects the medicine. Take it exactly as prescribed and do not stop early on your own. If you miss a dose, ask your doctor or pharmacist what to do. Store it below 30°C, away from light and moisture, and out of reach of children.
Side effects of Acifix
Acifix is generally well tolerated in short-term and long-term studies, but it may sometimes cause side effects. These include headache, diarrhoea, abdominal pain, vomiting, constipation, dry mouth, increased or decreased appetite, muscle pain, drowsiness and dizziness. Tell your doctor or pharmacist if any of these bother you or do not go away. Seek medical advice for any unusual or severe symptom while taking this medicine.
Safety and precautions
Do not take Acifix if you are allergic to rabeprazole or any of its ingredients. It is contraindicated in pregnancy and during breastfeeding, so tell your doctor if you are pregnant, planning pregnancy or breastfeeding. A response to treatment does not rule out stomach or oesophageal malignancy, so the doctor should exclude this before starting treatment. People on long-term treatment, especially more than a year, should be kept under regular surveillance. Proton pump inhibitors, especially in high doses and over long durations, may modestly increase the risk of hip, wrist and spine fracture, mainly in the elderly or those with other risk factors. Ask your doctor first if you have any concerns.
Frequently asked questions
What is Acifix and what is it used for?
Acifix 20 mg enteric-coated tablet contains rabeprazole sodium, a proton pump inhibitor. It is used for active duodenal ulcer, active benign gastric ulcer, and erosive or ulcerative gastro-oesophageal reflux disease, including long-term management and symptomatic treatment of moderate to very severe reflux disease. The doctor decides if it is right for you.
Is Acifix safe in pregnancy or breastfeeding?
Acifix is contraindicated in pregnancy and during breastfeeding. Tell your doctor if you are pregnant, planning pregnancy or breastfeeding so another option can be considered. Do not start or stop this medicine without your doctor's advice.
Which medicines may interact with Acifix?
Acifix can interact with medicines whose absorption depends on stomach acid. It may lower the levels of ketoconazole or itraconazole, so your doctor may monitor you and adjust the dose. It should not be taken with atazanavir. No interaction was seen with liquid antacids. Tell your doctor or pharmacist about all medicines you take.
Symptomatic treatment of moderate to very severe gastro-esophageal reflux disease (symptomatic GERD)
Zollinger-Ellison Syndrome
In combination with appropriate antibacterial therapeutic regimens for the eradication of Helicobacter pylori in patients with peptic ulcer disease.
Pharmacology
Rabeprazole suppresses gastric acid secretion by inhibiting the gastric H+/K+-ATPase at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, Rabeprazole has been characterized as a gastric proton-pump inhibitor.
Dosage & Administration
Active Duodenal Ulcer and Active Benign Gastric Ulcer: The recommended oral dose for both bioactive duodenal ulcer and active benign gastric ulcer is 20 mg to be taken once daily in the morning. Most patients with active duodenal ulcer heal within four weeks. However, a few patients may require an additional four weeks of therapy to achieve healing. Most patients with active benign gastric ulcer heal within six weeks. However, again a few patients may require an additional six weeks of therapy to achieve healing.
Erosive or Ulcerative Gastro-Esophageal Reflux Disease (GERD): The recommended oral dose for this condition is 20 mg to be taken once daily for four to eight weeks.
Gastro-Esophageal Reflux Disease Long-term Management (GERD Maintenance): For long-term management, a maintenance dose of rabeprazole sodium 20 mg or 10 mg once daily can be used depending upon patient response.
Symptomatic treatment of moderate to very severe Gastro-Esophageal Reflux Disease (symptomatic GERD): 10 mg once daily in patients without oesophagitis. If symptom control has not been achieved during four weeks, the patient should be further investigated. Once symptoms have resolved, subsequent symptom control can be achieved using an on-demand regimen taking 10 mg once daily when needed.
Treatment of GERD in pediatric patients 1 to 11 years of age (Less than 15 kg): 5 mg once daily for 12 weeks with the option to increase to 10 mg if inadequate response.
Treatment of GERD in pediatric patients 1 to 11 years of age (15 kg or more): 10 mg once daily for 12 weeks.
Zollinger-Ellison Syndrome: The recommended adult starting dose is 60 mg once a day. The dose may be titrated upwards to 120 mg/day based on individual patient needs. Single daily doses up to 100 mg/day may be given. 120 mg dose may require divided doses, 60 mg twice daily. Treatment should continue for as long as clinically indicated.
Eradication of H. pylori: Patients with H. pylori infection should be treated with eradication therapy. The following combination given for 7 days is recommended. Rabeprazole sodium 20 mg twice daily, clarithromycin 500 mg twice daily and amoxicillin 1g twice daily.
Interaction
Respite produces a profound and long-lasting inhibition of gastric acid secretion. An interaction with a compound whose absorption is pH dependent may occur. Co-administration of Acifix with ketoconazole or itraconazole may result in a significant decrease in antifungal plasma levels. Therefore individual patients may need to be monitored to determine if a dosage adjustment is necessary when ketoconazole or itraconazole are taken concomitantly with Respite. No interaction with liquid antacids was observed. The absorption of atazanavir is pH-dependent. Therefore PPIs, including rabeprazole, should not be co-administered with atazanavir.
Contraindications
Hypersensitivity to the active substance or to any of the excipients. Rabeprazole is contra-indicated in pregnancy and during breastfeeding.
Side Effects
In general, Acifix is well-tolerated in both short-term and long-term studies. Acifix may sometimes cause headache, diarrhoea, abdominal pain, vomiting, constipation, dry mouth, increased or decreased appetite, muscle pain, drowsiness, dizziness.
Pregnancy & Lactation
US FDA pregnancy category 'C'. Studies have been performed in animals and have revealed no evidence of impaired fertility or harm to the fetus due to Rabeprazole. There are however, no adequate and well-controlled studies in pregnant women. Rabeprazole is likely to be excreted in human milk, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Precautions & Warnings
Symptomatic response to therapy with Acifix does not preclude the presence of gastric or oesophageal malignancy, therefore the possibility of malignancy should be excluded prior to commencing treatment with Acifix 20 mg Gastro-resistant Tablets.
Patients on long-term treatment (particularly those treated for more than a year) should be kept under regular surveillance.
Proton pump inhibitors, especially if used in high doses and over long durations (>1 year), may modestly increase the risk of hip, wrist and spine fracture, predominantly in the elderly or in presence of other recognised risk factors. Observational studies suggest that proton pump inhibitors may increase the overall risk of fracture by 10–40%. Some of this increase may be due to other risk factors. Patients at risk of osteoporosis should receive care and they should have an adequate intake of vitamin D and calcium.
A risk of cross-hypersensitivity reactions with other proton pump inhibitor or substituted benzimidazoles cannot be excluded.
Patients should be cautioned that Acifix gastro-resistant tablets should not be chewed or crushed, but should be swallowed whole.
There have been post marketing reports of blood dyscrasias (thrombocytopenia and neutropenia). In the majority of cases where an alternative aetiology cannot be identified, the events were uncomplicated and resolved on discontinuation of rabeprazole.
Hepatic enzyme abnormalities have been seen in clinical trials and have also been reported since market authorisation. In the majority of cases where an alternative aetiology cannot be identified, the events were uncomplicated and resolved on discontinuation of rabeprazole.
No evidence of significant drug related safety problems was seen in a study of patients with mild to moderate hepatic impairment versus normal age and sex matched controls. However because there are no clinical data on the use of rabeprazole in the treatment of patients with severe hepatic dysfunction the prescriber is advised to exercise caution when treatment with Acifix 20mg Gastro-resistant. Tablets is first initiated in such patients.
Co-administration of atazanavir with Acifix is not recommended.
Treatment with proton pump inhibitors, including rabeprazole, may possibly increase the risk of gastrointestinal infections such as Salmonella, Campylobacter and Clostridium difficile.
Hypomagnesaemia: Severe hypomagnesaemia has been reported in patients treated with PPIs like rabeprazole for at least three months, and in most cases for a year. Serious manifestations of hypomagnesaemia such as fatigue, tetany, delirium, convulsions, dizziness and ventricular arrhythmia can occur but they may begin insidiously and be overlooked. In most affected patients, hypomagnesaemia improved after magnesium replacement and discontinuation of the PPI. For patients expected to be on prolonged treatment or who take PPIs with digoxin or drugs that may cause hypomagnesaemia (e.g., diuretics), health care professionals should consider measuring magnesium levels before starting PPI treatment and periodically during treatment.
Influence on vitamin B12 absorption: Acifix, as all acid-blocking medicines, may reduce the absorption of vitamin B12 (cyanocobalamin) due to hypo- or a- chlorhydria. This should be considered in patients with reduced body stores or risk factors for reduced vitamin B12 absorption on long-term therapy or if respective clinical symptoms are observed.
Subacute cutaneous lupus erythematosus (SCLE): Proton pump inhibitors are associated with very infrequent cases of SCLE. If lesions occur, especially in sun-exposed areas of the skin, and if accompanied by arthralgia, the patient should seek medical help promptly and the health care professional should consider stopping Acifix. SCLE after previous treatment with a proton pump inhibitor may increase the risk of SCLE with other proton pump inhibitors.
Interference with laboratory tests: Increased Chromogranin A (CgA) level may interfere with investigations for neuroendocrine tumours. To avoid this interference, Acifix 20mg Gastro-resistant Tablets treatment should be stopped for at least 5 days before CgA measurements. If CgA and gastrin levels have not returned to reference range after initial measurement, measurements should be repeated 14 days after cessation of proton pump inhibitor treatment.
Overdose Effects
The maximum established exposure has not exceeded 60 mg twice daily, or 160 mg once daily. Effects are generally minimal, representative of the known adverse event profile and reversible without further medical intervention. No specific antidote is known. Acifix is extensively protein bound and is, therefore, not dialysable. As in any case of overdose, treatment should be symptomatic and general supportive measures should be utilised.
Storage Conditions
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.
Alternative brands of Rabeprazole Sodium
Other brands with the same generic name, cheapest first.